Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this


  1. 1. Dr. Barnes, there is currently no cure for AD and no disease-modifying treatment, so the current best hope lies in identifying prevention strategies. We believe our formulation will help By 2050, as many as 16 million Americans will have Alzheimer's and the cost of care will surpass $1 trillion annually."
  2. 2. The food and drug administration (FDA) has approved two drugs specifically to treat symptoms of alzheimer's disease. Cholinesterase inhibitors Memantine Sold under the brand namenda by forest laboratories inc and germany's merz pharma, the drug had U.S.A Sales of about $1.2 billion last year. For the study, researchers culled through published studies, presentations at medical meetings and other sources to find studies that looked at the effectiveness of the drug memantine, namenda's generic form, in patients with mild alzheimer's disease. They found that memantine worked no better than a dummy pill at treating the disease.
  3. 3. AB1-40 Under the microscope, there were widespread fatty deposits in small blood vessels, dead and dying brain cells, and abnormal protein amyloid deposits in and around cells.
  4. 4. Act on Extracellular neuritic amyloid plaques Act on intracellular neurofibrillary tangles Act as cholinesterase inhibitor
  5. 5.  The value of the Alzheimer’s disease market across the seven major markets was $4.7bn in 2009 and is forecast to reach $11.9bn by 2019. Future market growth is set to be driven by the first disease-modifying drugs, given their significant price premium, likely therapeutic role as an adjunctive and potential utility in prodromal Alzheimer's diseaseDatamonitor forecasts that the current late-stage pipeline will yield three blockbusters, but this is by no means guaranteed considering the high risk of failure in Phase III Alzheimer’s disease trials. Of the pipeline drugs, Datamonitor believes that bapineuzumab and solanezumab have the most commercial and clinical potential.Datamonitor expects the symptomatic market will remain active in this disease. New symptomatic entrants to the market will include Aricept patch and the first-in-class 5-HT6 receptor antagonist SB-742457.
  6. 6. Worldwide, there are over 1000 published animal and human studies, both in vivo and in vitro in which the effects of curcumin on various diseases have been examined. Studies include epidemiological, basic and clinical research on AD.
  7. 7.      We took advantage of existing knowledge of curcumin and literature associated with its limitations. The biggest limitation is its solubility and hence the absorption when consumed orally. Stability is another issue CUBX has curcumin properties in it Our Hybrid Drug works Synergistically for two pathological hallmark of AD i.e extracellular neuritic amyloid plaques and intracellular neurofibrillary tangles.
  8. 8.     We resolved the issue of solubility and stability of it Our CUBXZIL molecule is soluble in water Our CUBXZIL is not altered by any chemical Our CUBXZIL is stable
  9. 9. Progressive Stages of Alzheimer’s Disease Stage 1. ( Early or Mild):       Short term memory problems May be unable to find the right words Forgets familiar names and telephone numbers Begins to write reminders but loses notes Shows preference for familiar things (Wears the same clothes, Avoids going out) Judgment may be impaired (May dress inappropriately for the weather) We must try this drug to avoid progression
  10. 10. Progressive Stages of Alzheimer’s Disease Stage 2a. (Middle or Moderate)):     Deterioration of ability to initiate and sequence purposeful activities like bathing and driving Sleep disturbance with restlessness at night Begins to neglect health and hygiene Needs directions to function in familiar surroundings We must try this drug to avoid progression
  11. 11. Progressive Stages of Alzheimer’s Disease Stage 2b. (Middle or Moderate)       May lose ability to perform daily skills (like buttoning a shirt or using a knife & fork) May need to be told each step of a former routine act (like brushing teeth or getting dressed) May walk with a shuffling gait or may seem “glued to the floor” due to a physical inability to walk Often needs physical assistance with activities of daily living (dressing, bathing, eating) Needs protection and supervision May lose the ability to read or write
  12. 12. Progressive Stages of Alzheimer’s Disease Stage 3. (Late or Final):          Can’t walk May discontinue talking or be unable to talk Trouble swallowing May have seizures Incontinence May make loud unintelligible negative noises or sounds Complete withdrawal or apathy May lose control of outer extremities Unable to survive without total care WE MUST ACT BEFORE THIS
  13. 13. Alzheimer’s is the fifth leading cause of disease death in the U.S. Our molecule is really affordable to use. It is safe and is reported to help. Become part of the solution and bring an end to this devastating disease! I will be really be glad even if I would able to contribute a little
  14. 14.                          Generic Brand Approved For and Side Effects donepezil Aricept All stages Nausea, vomiting, loss of appetite and increased frequency of bowel movements. galantamine Razadyne Mild to moderate Nausea, vomiting, loss of appetite and increased frequency of bowel movements. memantine Namenda Moderate to severe Headache, constipation, confusion and dizziness. rivastigmine Exelon Mild to moderate Nausea, vomiting, loss of appetite and increased frequency of bowel movements. tacrine Cognex Mild to moderate Possible liver damage, nausea, and vomiting. vitamin E Not applicable Not approved Can interact with medications prescribed to lower cholesterol or prevent blood clots; may slightly increase risk of death.
  15. 15. At this point we can not disclose the full and final information about our nanomedicine compound drug.
  16. 16.    Since ours is showing great results for arthritis and cancer. Our is not formulated in any kind of protein Our is more stable and more potent It is safe and we are looking for clinical collaboration. Doctors, organizations or community help
  17. 17.    To treat inflammation To treat stress To treat cholinesterase inhibitor
  18. 18. Dr. Mewa Singh LAETC, LSU Campus Baton Rouge, LA 